Sekiya Hiroaki, Koga Shunsuke, Murakami Aya, Kawazoe Miki, Kim Minji, Martin Nicholas B, Uitti Ryan J, Cheshire William P, Wszolek Zbigniew K, Dickson Dennis W
From the Department of Neuroscience (H.S., S.K., A.M., M. Kawazoe, N.B.M., D.W.D.), Mayo Clinic, Jacksonville, FL; Division of Neurology (H.S.), Kobe University Graduate School of Medicine; Department of Neurology (A.M.), Kansai Medical University Hirakata, Japan; Departments of Artificial Intelligence and Informatics Research (M. Kim) and Neurology (R.J.U., W.P.C., Z.K.W.), Mayo Clinic, Jacksonville, FL.
Neurology. 2023 Dec 12;101(24):e2460-e2471. doi: 10.1212/WNL.0000000000207905. Epub 2023 Oct 10.
The second consensus criteria in 2008 have been used in diagnosing multiple system atrophy (MSA). The International Parkinson and Movement Disorder Society (MDS) proposed new diagnostic criteria for MSA in 2022. This study aimed to compare the diagnostic accuracy between these 2 criteria and validate the clinical utility of the newly proposed criteria for MSA.
We conducted a retrospective autopsy cohort study of consecutive patients with a clinical or pathologic diagnosis of MSA from the Mayo Clinic brain bank between 1998 and 2021. We studied 352 patients (250 pathologically diagnosed MSA and 102 non-MSA); MDS criteria and the second consensus criteria were applied. The sensitivity, specificity, and area under the curve (AUC) of receiver operating characteristic curves were compared between these criteria. Comparison was conducted between clinical subtypes and among clinically challenging cases (those with different clinical diagnoses or those with suspected but undiagnosed MSA before death). We also used machine learning algorithm, eXtreme Gradient Boosting, to identify clinical features contributing diagnostic performance.
The sensitivity and specificity of clinically established and probable MSA by the MDS criteria were 16% and 99% and 64% and 74%, respectively. The sensitivity and specificity of probable MSA and possible MSA by the second consensus criteria were 72% and 52% and 93% and 21%, respectively. The AUC of MDS clinically probable MSA was the highest (0.69). The diagnostic performance did not differ between clinical subtypes. In clinically challenging cases, MDS clinically established MSA maintained high specificity and MDS clinically probable MSA demonstrated the highest AUC (0.62). MRI findings contributed to high specificity. In addition, combining core clinical features with 2 or more from any of the 13 supporting features and the absence of exclusion criteria also yielded high specificity. Among supporting features, rapid progression was most important for predicting MSA pathology.
The MDS criteria showed high specificity with clinically established MSA and moderate sensitivity and specificity with clinically probable MSA. The observation that high specificity could be achieved with clinical features alone suggests that MSA diagnosis with high specificity is possible even in areas where MRI is not readily available.
2008年的第二版共识标准已被用于诊断多系统萎缩(MSA)。国际帕金森和运动障碍协会(MDS)于2022年提出了MSA的新诊断标准。本研究旨在比较这两种标准的诊断准确性,并验证新提出的MSA标准的临床实用性。
我们对1998年至2021年间梅奥诊所脑库中临床或病理诊断为MSA的连续患者进行了一项回顾性尸检队列研究。我们研究了352例患者(250例经病理诊断为MSA,102例非MSA);应用了MDS标准和第二版共识标准。比较了这些标准之间的敏感性、特异性和接受者操作特征曲线下面积(AUC)。在临床亚型之间以及临床具有挑战性的病例(那些临床诊断不同或生前疑似但未诊断为MSA的病例)之间进行了比较。我们还使用了机器学习算法极限梯度提升来识别有助于诊断性能的临床特征。
根据MDS标准,临床确诊和可能的MSA的敏感性和特异性分别为16%和99%以及64%和74%。根据第二版共识标准,可能的MSA和疑似MSA的敏感性和特异性分别为72%和52%以及93%和21%。MDS临床可能的MSA的AUC最高(0.69)。诊断性能在临床亚型之间没有差异。在临床具有挑战性的病例中,MDS临床确诊的MSA保持高特异性,MDS临床可能的MSA表现出最高的AUC(0.62)。MRI结果有助于提高特异性。此外,将核心临床特征与13项支持特征中的2项或更多项相结合且无排除标准也产生了高特异性。在支持特征中,快速进展对于预测MSA病理最为重要。
MDS标准在临床确诊的MSA中显示出高特异性,在临床可能的MSA中显示出中等敏感性和特异性。仅通过临床特征就能实现高特异性这一观察结果表明,即使在MRI不易获得的地区,也有可能进行具有高特异性的MSA诊断。